The Latest

Vista Current Coverage

Health Insurance Innovations (HIIQ) Presents “9 Straight Quarters of Record Revenue & Adjusted Earnings”

Tampa, FL based Health Insurance Innovations, Inc. (NasdaqCM: HIIQ) is a market leader in developing innovative health insurance products that are affordable and meet the needs of millions of health insurance plan shoppers. HIIQ develops insurance products through partnerships with best-in-class insurance companies and markets...

Health Insurance Innovations (HIIQ) To Present at Cantor Fitzgerald Global Healthcare Conference Monday September 25th In NYC!

Tampa, FL based Health Insurance Innovations, Inc. (NasdaqCM: HIIQ) is a market leader in developing innovative health insurance products that are affordable and meet the needs of millions of health insurance plan shoppers. HIIQ develops insurance products through partnerships with best-in-class insurance companies and markets...

Disney & Chase Renew Co-Branding Relationship!

Chase is the U.S. consumer and commercial banking business of JPMorgan Chase & Co. (JPM), a leading global financial services firm with assets of $2.6 trillion and operations worldwide. Chase serves nearly half of America’s households with a broad range of financial services, including personal...

“Wild & Crazy?” Or “Calm & Sane?”

No we are not suggesting that the woman pictured is “Wild & Crazy”  or  for that matter “Calm & Sane”, but we are confirming that Vista Partners Weekly Market Update for Week Ending September 2017 called “Wild & Crazy” is available. It includes a quick...

Novel Breast Cancer Therapeutics Innovator Atossa (NasdaqCM: ATOS) Reports “All Objectives Successfully Met In Phase 1 Study”

  Atossa Genetics Inc. (NasdaqCM: ATOS), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, reported preliminary results this week from its Phase 1 dose escalation study of its proprietary topical Endoxifen. The Phase 1 study was...

Sarepta Announces Positive Results…Shares Rise

Sarepta Therapeutics, Inc. (SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicines to treat rare neuromuscular diseases, today announced muscle biopsy results from its 4053-101 study, a Phase 1/2 first-in-human study conducted in Europe to assess the safety, tolerability,...

Dow 30

22,350
close
+0.4%
Week
+13.1%
YTD

Dow 30

22,350
close
+0.4%
Week
+13.1%
YTD

Dow 30

22,350
close
+0.4%
Week
+13.1%
YTD

Dow 30

22,350
close
+0.4%
Week
+13.1%
YTD

Dow 30

22,350
close
+0.4%
Week
+13.1%
YTD